Technical Data
IL-32, ID (Interleukin-32, Natural Killer Cells Protein 4, Tumor Necrosis Factor alpha-inducing Factor, IL32, NK4, TAIF)
Interleukin-32 (IL-32) was initially identified as a transcript (NK4) selectively expressed in lymphocytes and NK cells, whose expression is increased following activation by IL-2. It was later re-isolated from an IL-18-treated lung carcinoma cell line and re-named IL-32. IL-32 is unusual in that it does not share sequence homology with known cytokine families and is highly expressed in immune tissues, existing in at least four differentially spliced isoforms. Because treatment of human monocytic and mouse macrophage cells with IL-32 induces several proinflammatory cytokines such as TNF-a, IL-8 and MIP-2, and because it is induced in human peripheral lymphocyte cells after mitogen stimulation and in epithelial cells by IFNg, it has been suggested that IL-32 may play a role in autoimmune and inflammatory diseases such as rheumatoid arthritis.

Suitable for use in ELISA and Western Blot. Other applications not tested.

Recommended Dilution:
Western Blot: 2.5-5ug/ml
Optimal dilutions to be determined by the researcher.

Positive Control:
Jurkat cell lysate

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
50ug-20CBlue IceHumanRabbit
Synthetic peptide corresponding to 16aa from near the center of human IL-32.
Supplied as a liquid in PBS, 0.02% sodium azide.
Recognizes human IL-32. Species Crossreactivity: mouse.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Dahl CA, et al (1992) J. Immunol. 148:597-603. 2. Kim S-H, et al (2005) Immunity. 22:131-42. 3. Cagnard N, et al (2005) Eur. Cyto. Network. 16:289-92.